Samsung Biologics Bets $2.0 Billion on Swiss Peptide Maker PolyPeptide to Enter the GLP-1 Supply Chain
Samsung Biologics (207940.KS), the Songdo-based contract drug manufacturer within Korea's Samsung group, has agreed to acquire 100% of PolyPeptide Group AG, a Swiss-headquartered contract developer and manufacturer of therapeutic peptides, in the largest M&A ever struck by a Korean pharmaceutical or...
- 02
GC Corp (006280.KS) Q1 2026: Operating Profit Surges 47% While Subsidiary Exit and Tax Reversal Drag Net Income 31% Lower
GC Corp posted a 47% surge in Q1 2026 operating profit to KRW 11.7 billion on 13.5% revenue growth, but net income attributable to controlling shareholders fell 31% due to a subsidiary exit and a KRW 14 billion adverse tax swing.
- 03
Micron Locks In 3-to-5-Year Automotive AI Memory Deals with Hyundai Mobis and Samsung Harman
Micron signed 3-5 year supply deals with Hyundai Mobis (012330.KS) and Samsung Harman for ADAS memory. TrendForce projects SLC NAND prices could surge 120-170% in H2 2026.
- 04
Korea Aerospace Industries Completes T-50i Deliveries to Indonesia — KF-21 Export Deal Next in Line
KAI delivered 6 T-50i jets to Indonesia in July 2026 (total: 22). Indonesia may next buy 16 KF-21 fighters (~KRW 3T). KAI stock is 27% below analyst consensus target.
- 05
Starbucks Korea's First Union Forms as Q2 Operating Loss Looms — Emart (139480.KS) Faces Compounding Risk
Korea's first coffee-chain union forms at Starbucks Korea as Q2 2026 brings an expected ₩22.9B operating loss — a dual shock for Emart (139480.KS), which owns 67.5% of SCK.
- 06
LG Display (034220.KS) Q2 2026 Earnings Preview: Restructuring Trough on July 22 Before Apple OLED Ramp
LG Display reports Q2 2026 on July 22. Consensus: OP loss ₩83–119B on restructuring. Analysts see Q2 as the trough before H2 Apple OLED ramp — BOE shut out of premium models.
- 07
Hyundai Motor and Kia Q2 2026 Earnings Preview: Fire, Tariffs, and a Surprising Divergence
Hyundai Motor reports Q2 on July 23, Kia on July 24. Consensus sees Hyundai OP down ~14% from a factory fire and tariffs; Kia up ~1% on hybrid strength. Three things to watch.
- 08
Woori Financial (316140.KS) Q2 2026 Earnings Preview: Indonesia Provisions Booked, ₩958B Rebound on July 24
Woori Financial reports H1 2026 results on July 24 at 16:00 KST. Q2 consensus: ~₩958B (approx. +2% YoY per FnGuide). CET1 record 13.6%; H2 buyback up to ₩350B in view.
- 09
Shinhan Financial Group (055550.KS) Q2 2026 Earnings Preview: NIM Lift, ₩5T Milestone, and Lotte Wildcard
Shinhan Financial Group reports Q2 on July 24. Consensus net profit ~₩1.61T (+4% YoY). NIM +1bp to 1.94%, CET1 ~13.5%, and Lotte Non-Life deal are the key watch points.
- 10
Hana Financial Group Q2 2026 Earnings Preview: Record Profit, NIM Expansion, and ₩650B H2 Buyback
Hana Financial reports Q2 2026 results July 24. Consensus ₩1.22–1.25T net income (+4–6% YoY), record quarter. Watches: NIM +3bp, ₩650B H2 buyback, Dunamu CET1.
- 11
Foreign Investors Net-Sold ₩12.4 Trillion in Korean Stocks in July — but They Are Buying Index ETFs
Foreign investors net-sold ₩12.44T in Korean equities in July (₩12.1T KOSPI + ₩338.1B KOSDAQ) but bought a net ₩593.7B in Korean ETFs. We decode what this divergence signals.
- 12
Dongwon Industries (006040.KS) Q1 2026: ₩2.53T Revenue, Net Profit Surges 51%
Dongwon Industries Q1 2026: revenue ₩2.53T (+9.1%), operating profit ₩146.2B (+17.1%), net income ₩112.9B (+51%). B2B packaging and logistics outperform; StarKist maintains 46% US tuna market share.
- 13
KB Financial (105560.KS) Q2 2026 Earnings Preview: Record Profit, Rate Hike, and H2 Buyback
KB Financial's H1 2026 earnings conference is July 23 at 16:00 KST. Consensus Q2 net profit ₩1.91T (+10%) — here are three things Korea investors must watch.
- 14
South Korea's Biggest FX Overhaul Since 1997 Opens Won to Foreign Investors — What It Means for KOSPI
South Korea unveiled its biggest forex reform since 1997: foreigners can open won-denominated accounts overseas from Jan 2027. Here's what KOSPI investors need to know.
- 15
Korea Market Week Ahead (July 20–25): SK Hynix Q2 Wednesday, Bank Earnings, Homeplus Verdict
SK Hynix Q2 lands Wed July 22 (OP consensus ₩60–65T, +551–606% YoY). KB Financial call Thu July 23. Homeplus ruling expected. Four key events July 20–25 plus CXMT IPO July 27.
- 16
HLB (028300.KS) Q1 2026: Net Loss Narrows 40%, FDA Ruling Looms
HLB's Q1 2026 consolidated net loss narrowed 40% to ₩40.9B as cost discipline offset declining drug revenues. The biotech's FDA rivoceranib ruling for hepatocellular carcinoma is the key catalyst to watch.
- 17
KB Report: Korea Solo Households Rotated Into Stocks at Peak
KB Report: Korea Solo Households Rotated Into Stocks at Peak
- 18
Alteogen ALT-B4 Powers Keytruda SC as Celltrion and Samsung Bioepis Field Rival Korean SC Platforms
Alteogen ALT-B4 powers Keytruda SC with up to $890M MSD milestones. Celltrion and Samsung Bioepis now field rival Korean SC platforms ahead of Keytruda's 2028 patent cliff.
- 19
SKHY Lands in 11 Korean Active ETFs Six Days After Nasdaq Debut — Three Things to Watch Ahead of Q2 Earnings
SK Hynix ADR (SKHY) entered 11 Korean active ETFs within six days of its July 10 Nasdaq debut. Q2 results come July 22 — three factors every investor must track.
LineVest Daily
Get this wrap in your inbox every morning.
One email before the U.S. open — the earnings, filings, and guidance changes that matter, in plain English. Free.
Subscribe free